FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome
Go back to FDA places clinical hold on Regenxbio's RGX-121 gene therapy for Hunter Syndrome| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 7.88 -0.15 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.03 | 52 Week High | $25.00 | |||
| Open | $8.24 | 52 Week Low | $7.07 | |||
| Day High | $8.31 | P/E | N/A | |||
| Day Low | $7.76 | EPS | $0.00 | |||
| Volume | 1,115,691 | |||||
